Il non ha versiones revidite de iste pagina, dunque su qualitate forsan non ha essite verificate.

AOH1996 es un chimiotherapia experimental anticancere. Iste molecula inhibi un forma particular del antigene nuclear del cellulas proliferante (en) (PCNA), qui es specific al cellulas canceree.[1][2][3][4]

AOH1996
instantia de: type of chemical entity[*]
subclasse de: composito chimic


Le proteina PCNA es crucial pro reparar le ADN de omne cellulas. Le tractamento presenta le interesse de affectar solmente cellulas tumoral.[5] Poterea ager contra canceres del pectore, prostata, cerebro, ovarios, collo uterin, pelle e pulmon.[6][7]

Su nomine es un hominaje a Anna Olivia Healy, un filia de 9 annos morte in 2006 de consequentias de un neuroblastoma. Le fundos colligite per su parentes ha adjutate a disveloppar iste medicamento.[6][8]

Referentias

modificar
  1. Malkas LH, et al. PCNA Inhibitors. Patent WO 2017/049206
  2. "Arginine shortage induces replication stress and confers genotoxic resistance by inhibiting histone H4 translation and promoting PCNA ubiquitination" (March 2023). Cell Reports 42 (4): 112296. PMID 36961817. 
  3. "Small molecule targeting of transcription-replication conflict for selective chemotherapy" (August 2023). Cell Chemical Biology. doi:10.1016/j.chembiol.2023.07.001. 
  4. AOH1996 for the Treatment of Refractory Solid Tumors.
  5. "The Anticancer Activity of a First-in-class Small-molecule Targeting PCNA" (December 2018). Clinical Cancer Research 24 (23): 6053–6065. PMID 29967249. 
  6. 6,0 6,1 Anna (9) starb an Krebs – jetzt ist die Wunderpille nach ihr benannt (germano). 20 Minuten (2023-08-02).
  7. 'Cancer-killing pill' that appears to 'annihilate' solid tumours is now being tested on humans (anglese).
  8. AOH-1996 Is Here!. ANNA Fund (2021-12-21).